Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume

Department of Neurology, School of Medicine, University of California, Davis, Davis, CA, USA.
Neurobiology of aging (Impact Factor: 4.85). 12/2011; 33(6):1124.e31-41. DOI: 10.1016/j.neurobiolaging.2011.08.016
Source: PubMed

ABSTRACT Hippocampal injury in the Alzheimer's disease (AD) pathological process is region-specific and magnetic resonance imaging (MRI)-based measures of localized hippocampus (HP) atrophy are known to detect region-specific changes associated with clinical AD, but it is unclear whether these measures provide information that is independent of that already provided by measures of total HP volume. Therefore, this study assessed the strength of association between localized HP atrophy measures and AD-related measures including cerebrospinal fluid (CSF) amyloid beta and tau concentrations, and cognitive performance, in statistical models that also included total HP volume as a covariate. A computational technique termed localized components analysis (LoCA) was used to identify 7 independent patterns of HP atrophy among 390 semiautomatically delineated HP from baseline magnetic resonance imaging of participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Among cognitively normal participants, multiple measures of localized HP atrophy were significantly associated with CSF amyloid concentration, while total HP volume was not. In addition, among all participants, localized HP atrophy measures and total HP volume were both independently and additively associated with CSF tau concentration, performance on numerous neuropsychological tests, and discrimination between normal, mild cognitive impairment (MCI), and AD clinical diagnostic groups. Together, these results suggest that regional measures of hippocampal atrophy provided by localized components analysis may be more sensitive than total HP volume to the effects of AD pathology burden among cognitively normal individuals and may provide information about HP regions whose deficits may have especially profound cognitive consequences throughout the AD clinical course.

Download full-text


Available from: Holly D Soares, Jul 02, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We examined in vivo evidence of axonal degeneration in association with neuronal pathology in Alzheimer's disease (AD) through analysis of fornix microstructural integrity and measures of hippocampal subfield atrophy. Based on known anatomical topography, we hypothesized that the local thickness of subiculum and CA1 hippocampus fields would be associated with fornix integrity, reflecting an association between AD-related injury to hippocampal neurons and degeneration of associated axon fibers. To test this hypothesis, multi-modal imaging, combining measures of local hippocampal radii with diffusion tensor imaging (DTI), was applied to 44 individuals clinically diagnosed with AD, 44 individuals clinically diagnosed with mild cognitive impairment (MCI), and 96 cognitively normal individuals. Fornix microstructural degradation, as measured by reduced DTI-based fractional anisotropy (FA), was prominent in both MCI and AD, and was associated with reduced hippocampal volumes. Further, reduced fornix FA was associated with reduced anterior CA1 and antero-medial subiculum thickness. Finally, while both lesser fornix FA and lesser hippocampal volume were associated with lesser episodic memory, only the hippocampal measures were significant predictors of episodic memory in models including both hippocampal and fornix predictors. The region-specific association between fornix integrity and hippocampal neuronal death may provide in vivo evidence for degenerative white matter injury in AD: axonal pathology that is closely linked to neuronal injury.
    Frontiers in Aging Neuroscience 04/2012; 4:1. DOI:10.3389/fnagi.2012.00001 · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Identifying associations between the shape properties of brain regions, measured from magnetic resonance imaging (MRI), and numerical measures of neurodegenerative disease burden can clarify whether disease processes lead to distinctive spatial patterns of brain atrophy. However, prior methods for identifying such associations between shape and clinical variables either failed to summarize shape patterns into a concise set of summary measurements, or risked failing to discover such associations by extracting summary shape features blinded to the clinical variables. We present a method that overcomes these limitations by directly searching for a small set of linear shape features-shape regression components-that simultaneously account for a large amount of population shape variability and are highly correlated with a numerical clinical variable of interest. When applied to hippocampi of 299 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants, the method identified correlations between hippocampal atrophy and markers of AD pathology and cogniton that were stronger than, and covered a more extended spatial region than, those identified by competing approaches.
    Conference proceedings: ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference 08/2012; 2012:2680-3. DOI:10.1109/EMBC.2012.6346516
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We propose a new method to maximize biomarker efficiency for detecting anatomical change over time in serial MRI. Drug trials using neuroimaging become prohibitively costly if vast numbers of subjects must be assessed, so it is vital to develop efficient measures of brain change. A popular measure of efficiency is the minimal sample size (n80) needed to detect 25% change in a biomarker, with 95% confidence and 80% power. For multivariate measures of brain change, we can directly optimize n80 based on a Linear Discriminant Analysis (LDA). Here we use a supervised learning framework to optimize n80, offering two alternative solutions. With a new medial surface modeling method, we track 3D dynamic changes in the lateral ventricles in 2,065 ADNI scans. We apply our LDA-based weighting to the results. Our best average n80 - in two-fold nested cross-validation - is 104 MCI subjects (95% CI: [94,139]) for a 1-year drug trial, and 75 AD subjects [64,102]. This compares favorably with other MRI analysis methods. The standard "statistical ROI" approach applied to the same ventricular surfaces requires 165 MCI or 94 AD subjects. At 2 years, the best LDA measure needs only 67 MCI and 52 AD subjects, versus 119 MCI and 80 AD subjects for the stat-ROI method. Our surface-based measures are unbiased: they give no artifactual additive atrophy over three time points. Our results suggest that statistical weighting may boost efficiency of drug trials that use brain maps.
    NeuroImage 01/2013; 70. DOI:10.1016/j.neuroimage.2012.12.052 · 6.13 Impact Factor